Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec once daily versus twice-daily long-acting insulin in adults with type 1 diabetes
ChiCTR1900027613Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin degludec, insulin glargine and insulin detemir in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Blood sugar before dinner. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
insulin degludecinsulin glargineinsulin detemir
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ChiCTR1900027613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027613.